Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 212-052-3 | CAS number: 756-79-6
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Neurotoxicity
Administrative data
- Endpoint:
- neurotoxicity: acute oral
- Type of information:
- experimental study
- Adequacy of study:
- supporting study
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- other: Scientifically acceptable study (QC)
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 1 978
- Report date:
- 1978
Materials and methods
- Principles of method if other than guideline:
- Evaluation of cholinesterase activity in blood plasma of rats animals after repeated oral administration (3 consecutive days) of the test substance
- GLP compliance:
- no
- Remarks:
- well documented study (QC)
- Limit test:
- no
Test material
- Reference substance name:
- Dimethyl methylphosphonate
- EC Number:
- 212-052-3
- EC Name:
- Dimethyl methylphosphonate
- Cas Number:
- 756-79-6
- Molecular formula:
- C3H9O3P
- IUPAC Name:
- dimethyl methylphosphonate
- Details on test material:
- - Name of test material (as cited in study report): a liquid, labelled "FAT 80 021B"
Constituent 1
Test animals
- Species:
- rat
- Strain:
- Sprague-Dawley
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: derived rats bred on tlie premises
- Age at study initiation: 35-49 days
- Weight at study initiation: mean bw of 301 for males and 206 in females
- Diet (e.g. ad libitum): a commercial diet BP Nutrition UK Ltd. Rat and House No. 1 Expanded diet was fed
- Housing: housed in boxes of 5
- Water (e.g. ad libitum): drinking water
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 21±2°C
no additional data
Administration / exposure
- Route of administration:
- oral: gavage
- Vehicle:
- water
- Details on exposure:
- PREPARATION OF DOSING SOLUTIONS:
The compound was mixed with tap water at the required concentrations and administered at a constant rate of 10 ml/kg. Control animals received the vehicle (tap water) only at the same rate. The concentration of the administered compoud in water was as follows: 0% in the control groups, 0.01% in the 1 mg/kg bw test group, 0.1% in the 10 mg/kg bw test group, 1.0% in the 100 mg/kg bw test group and 10.0% in the 1000 mg/kg bw test group. - Analytical verification of doses or concentrations:
- not specified
- Duration of treatment / exposure:
- the animals were given 3 consecutive daily doses
- Frequency of treatment:
- daily
Doses / concentrations
- Remarks:
- Doses / Concentrations:
0, 1, 10, 100 and 1000 mg/kg bw per day
Basis:
actual ingested
- No. of animals per sex per dose:
- 5 in each group (2 control groups and 4 test groups; the animals were treated and manipulated in two consecutive days with one control each times)
- Control animals:
- yes, concurrent vehicle
- Details on study design:
- Blood samples for plasma cholinesterase activity measurements were taken pretest and ½, 1, 2 and 4 hours after the third administration. Blood was obtained from the retro-orbital plexus under light anesthesia using ether/oxygen. No timed samples were obtained from one control male animal died under anesthetic at the ½ hour blood sampling on day 3.
Examinations
- Observations and clinical examinations performed and frequency:
- CLINICAL OBSERVATIONS
Following parameters were recorded daily: body weights, food consumption and clinical symptoms. - Specific biochemical examinations:
- CHOLINESTERASE ACTIVITY
LKB Reaction Rate Analyser - Neurobehavioural examinations performed and frequency:
- Not evaluated
- Sacrifice and (histo)pathology:
- All surviving rata were humanely killed after samples were completed. No autopsies were performed
- Other examinations:
- not applicable
- Positive control:
- none
- Statistics:
- Cholinesterase results were analyzed using Students' 't' test for independent variables, (Level of significance P<0.05)
Results and discussion
Results of examinations
- Clinical signs:
- effects observed, treatment-related
- Mortality:
- mortality observed, treatment-related
- Body weight and weight changes:
- no effects observed
- Food consumption and compound intake (if feeding study):
- no effects observed
- Food efficiency:
- not examined
- Water consumption and compound intake (if drinking water study):
- not examined
- Ophthalmological findings:
- not examined
- Clinical biochemistry findings:
- effects observed, treatment-related
- Behaviour (functional findings):
- not examined
- Gross pathological findings:
- not examined
- Neuropathological findings:
- not examined
- Other effects:
- not examined
- Description (incidence and severity):
- Migrated information from 'Further observations for developmental neurotoxicity study'
Details on results (for developmental neurotoxicity):- (migrated information) - Details on results:
- MORTALITY
One animal died in the control group during blood sampling (see above)
BODY WEIGHT
No adverse effect observed (see Table 1)
FOOD CONSUMPTION
No adverse effect observed (see Table 2)
CHOLINESTERASE ACTIVITY
Plasma cholinesterase levels were depressed in the highest dose group only (1000 mg/kg; see Table 3). In males there was an approximate reduction of 30% over the 4 hour period when compared to control values taken at the same time, and in females there was a 40 – 50% reduction. There was no effect on plasma cholinesterase levels in the other groups.
Effect levels
- Dose descriptor:
- NOEL
- Effect level:
- 100 mg/kg bw/day (actual dose received)
- Sex:
- male/female
- Basis for effect level:
- other: based on the significant reduced plasma cholinesterase activity at 1000 mg/kg bw
- Remarks on result:
- other: Generation: other: - null (migrated information)
Any other information on results incl. tables
Table 1: Mean daily body weights
Test groups |
Mean body weight on day (g) |
|||||
1 |
2 |
3 |
||||
Males |
Females |
Males |
Females |
Males |
Females |
|
Control 1 |
300 |
206 |
306 |
209 |
310 |
211 |
Control 2 |
298 |
212 |
303 |
215 |
311 |
221 |
1 mg/kg bw |
300 |
210 |
304 |
214 |
316 |
218 |
10 mg/kg bw |
299 |
210 |
309 |
209 |
311 |
215 |
100 mg/kg bw |
312 |
192 |
318 |
197 |
328 |
200 |
1000 mg/kg bw |
298 |
207 |
306 |
212 |
310 |
213 |
Table 2: Daily food consumption
Test groups |
Mean body weight on day (g/cage) |
|||||
1 |
2 |
3 |
||||
Males |
Females |
Males |
Females |
Males |
Females |
|
Control 1 |
26 |
17 |
26 |
19 |
17 |
10 |
Control 2 |
27 |
20 |
27 |
18 |
21 |
14 |
1 mg/kg bw |
24 |
19 |
25 |
17 |
21 |
12 |
10 mg/kg bw |
27 |
18 |
26 |
20 |
16 |
12 |
100 mg/kg bw |
28 |
16 |
25 |
16 |
19 |
13 |
1000 mg/kg bw |
26 |
16 |
25 |
17 |
16 |
10 |
Table 3: Mean plasma cholinesterase activity
Test groups |
Mean cholinesterase activity (m units/ml plasma) after |
|||||||
½ hour |
1 hour |
2 hours |
4 hours |
|||||
Males |
Females |
Males |
Females |
Males |
Females |
Males |
Females |
|
Control 1 |
478 |
1158 |
464 |
1082 |
443 |
1023 |
465 |
1070 |
Control 2 |
414 |
956 |
460 |
974 |
428 |
932 |
413 |
894 |
1 mg/kg bw |
474 |
1132 |
475 |
1193 |
445 |
1131 |
447 |
1075 |
10 mg/kg bw |
451 |
1117 |
457 |
1095 |
451 |
998 |
454 |
1070 |
100 mg/kg bw |
451 |
1222 |
468 |
1206 |
447 |
1100 |
432 |
1050 |
1000 mg/kg bw |
334*** |
553** |
322* |
561** |
323*** |
605* |
341** |
633** |
*: P<0.05; **: P<0.01; ***: P<0.001 |
Applicant's summary and conclusion
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.